Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $10 price target.
Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $10 price target.
Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $1.25 price target.
In addition, Seres is due to receive installment payments in 2025, as well as potential future payments based on VOWST net sale...
